

Aberration of *FHIT* Gene is Associated with Increased Tumor Proliferation and Decreased Apoptosis—Clinical Evidence in Lung and Head and Neck Carcinomas

Krešimir Pavelić,¹ Šimun Križanac,¹ Tamara Čačev,¹ Marijana Popović Hadžija,¹ Senka Radošević,² Ivana Crnić,¹ Sonja Levanat,¹ and Sanja Kapitanović¹

¹Ruder Bošković Institute, Division of Molecular Medicine, Zagreb, Croatia

²PLIVA d.d., Research & Development, Zagreb, Croatia

Accepted April 5, 2001

Abstract

Background: Human *FHIT* (fragile histidine triad) gene is highly conserved gene homologous to a group of genes identified in prokaryotes and eukaryotes. Loss of *FHIT* function may be important in the development and/or progression of various types of cancer.

Materials and Methods: We undertook a clinical study to analyze the relation between aberrant function of *FHIT* gene, tumor cell proliferation, and intensity of apoptosis as well as prognostic output in lung and squamous cell head and neck carcinoma (HNSCC). Status of *FHIT* gene, expression of p21^{waf1}, intensity of apoptosis, and cell proliferation were analyzed in HNSCC and lung carcinoma tissues by molecular genetic methods, immunohistochemistry, [³H]-thymidine labeling method, and FAC-Scan analysis in frozen and paraffin-embedded tissue sections.

Results: The majority of the malignant lung and HNSCC lesions displayed aberrant expression of *FHIT* gene, followed by low or negative expression of p21^{waf1}, and increased intensity of cell proliferation. Similar results were obtained on synchronous combinations of normal, precancerous, and

cancerous head and neck tissues. The observed changes increased with progression of these lesions. We examined tumor and corresponding normal tissue samples for microsatellite markers D3S1300 and D3S4103 to evaluate the loss of heterozygosity (LOH) at the *FHIT* gene loci. We found high percentage of LOH in both lung tumors and HNSCC (75% for D3S1300 and 79% for D3S4103 in lung cancer, and 87% for D3S1300 and 78% for D3S4103 in HNSCC). The median survival time of the patients suffering from lung cancer without *FHIT* protein expression was 22.46 months and that of the patients with *FHIT* expression 36.04 months. *FHIT*-negative cases tended to correlate with a worse prognosis, but this was not statistically significant. Median survival time of HNSCC patients without *FHIT* protein expression was 30.86 months and that of the patients with *FHIT* expression was 64.04 months ($p < 0.05$).

Conclusions: Our results show a correlation between aberrant *FHIT* expression, a low rate of apoptosis, and high tumor cell proliferation. Aberrant *FHIT* gene could be a prognostic marker in lung cancer.

Introduction

Sozzi et al. (1) identified the human *FHIT* (fragile histidine triad) gene using an exon trapping strategy from cosmids covering specific region at 3p14.2 involved in epithelial cancer cell lines (1,2). *FHIT* is a highly conserved gene homologous to a group of genes identified in prokaryotic and eukaryotic organisms. Occurrence of abnormal transcripts of the *FHIT* gene has been reported in various types of cancer (1–5). On the other hand, aberrant transcripts are sometimes found in non-neoplastic tissues. This suggests that the presence of abnormal *FHIT* transcripts, in terms of their frequency and variety, is not cancer-specific in lung carcinogenesis, and the abnormality may be

due to abnormal splicing and processing of the transcripts (6).

The *FHIT* gene contains the most common fragile site of the human genome FRA3B (3); it encompassing the FRA3B fragile region and encodes a protein of Mr 16,800 with diadenosine triphosphate hydrolase activity dependent on the conserved histidine triad encoded by exon 8 (7). The multiple genetic lesions within *FHIT* gene may be explained by the location of the gene within a fragile site, by definition highly susceptible to breakage induced by carcinogens (8).

In some tumors, particularly those associated with environmental carcinogens, alterations in the *FHIT* gene occur quite early in the development of cancer. In other cancers, *FHIT* inactivation seems to be a later event, possibly associated with progression to more aggressive neoplasias (9).

Loss of heterozygosity (LOH) at 3p14 has been observed frequently in squamous cell carcinomas of the head and neck (HNSCC) and lung cancers (10–13). Small cell lung tumors (80%) and non-small

Address correspondence and reprint requests to: Krešimir Pavelić, MD, PhD, Ruder Bošković Institute, Division of Molecular Medicine, Bijenička 54, P.O. Box 180, HR-10002 Zagreb, Croatia. Phone: 385 1 456 1010; Fax 385 1 456 1010; e-mail: pavelic@rudjer.irb.hr

cell lung cancers (40%) showed abnormalities in RNA transcripts of *FHIT*, and 76% of the tumors exhibited loss of *FHIT* alleles. Abnormal lung tumor transcripts lack two or more exons of the *FHIT* gene. These data suggest a critical (or at least important) role for the *FHIT* gene in lung carcinogenesis (4).

Given the concordance between the occurrence of LOH affecting microsatellite markers within the *FHIT* gene and abnormal *FHIT* transcript in tobacco-related cancers such as lung (1) and head and neck tumors (4,12), loss of one *FHIT* allele is likely to be a crucial step leading to loss of function of the gene. Sozzi et al. (14) showed that LOH affected at least one locus of the *FHIT* gene (observed in 80% tumors in the smokers but in only 22% tumors of non-smokers). These data indicate that FRA3B is a preferential target of tobacco smoke damage at a molecular level. Nonsmoker patients with *FHIT* abnormalities revealed a significant exposure to passive smoke, either at home or at work.

Siprashvili et al. (15) observed a suppression of tumorigenicity in cancer-derived cell lines, including tumor cell lines derived from gastric carcinomas, after restoring *FHIT* protein expression. *FHIT* gene transfer into lung cancer cell line H460 lacking *FHIT* protein expression resulted in revision of tumorigenicity, significant inhibition of cell growth, and a high rate of apoptosis-induced DNA strand breaks in stable clones. An increased level of p21^{waf1} protein paralleled by an up-regulation of p21^{waf1} transcripts was also found in *FHIT*-expressing clones compared with the H460 cell line (16). When delivered at high efficiency by a recombinant adenoviral vector, *FHIT* gene functions as a tumor suppressor gene both in vitro and in vivo. Over-expression of the *FHIT* gene significantly inhibits cell growth in various adenoviral vector *FHIT*-transduced human lung cancer cells and head and neck carcinoma cells with *FHIT* gene abnormalities, but not in normal human bronchial epithelial cells. Over-expression of *FHIT* gene induces cell apoptosis and alters cell-cycle processes. The cells accumulate *FHIT* protein in S-phase after transduction (17). *FHIT*-deficient mice develop a Muir-Torre-like syndrome (18). It is unclear whether this observation has any clinical relevance.

Here we undertook a clinical study to prove experimental data regarding the correlation between aberrant function of *FHIT* gene, tumor cell proliferation, intensity of programmed cell death (apoptosis), and prognostic output in lung and head and neck cancer.

Materials and Methods

Tumor Specimens

HNSCC. Tumor and adjacent normal specimens from patients with primary HNSCC were from Croatian Human Tumor Bank (19). Material from 74 patients

suffered from HNSCC (58 men aged 42–75 years and 16 women aged 50–73 years) was studied. Twenty-three samples were used for comparative study (*FHIT* gene status, p21^{waf1}, apoptosis, and [³H]-thymidine [³H]-thy labeling). Twenty-three different samples were used for loss of LOH analysis; in 27 samples, p21^{waf1} expression and apoptosis were compared with *FHIT* gene status. Samples were snap frozen in various stages and analyzed. None of patients included in this study had undergone any preoperative treatment.

There were also 12 patients with synchronous lesions: dysplasia, carcinoma in situ, and cancer of the head and neck (Table 1). Their samples were analyzed for *FHIT* gene status, p21^{waf1} expression, and apoptosis; the same fresh carcinoma samples were used in tumor kinetic assay immediately after surgery.

FHIT protein was analyzed immunohistochemically in 120 archival, paraffin-embedded samples (80 men aged 42–81 years and 40 women aged 57–79 years); 82 patients from this group were used for survival analysis.

LUNG CANCERS. A total of 48 lung carcinomas (20 squamous cell carcinomas, 10 adenocarcinomas, 12 large cell carcinomas, and 6 adenosquamous carcinomas) obtained from Croatian Human Tumor Bank were analyzed. These were obtained from patients treated surgically (32 men, aged 35–70 years, mean 60 years; and 16 women, aged 48–70, mean 59 years). Twenty tissue samples were used for comparative study (Table 2) and 28 informative samples were used for LOH analysis (Table 3). Eighty-two patients suffering from lung cancer were used for survival analysis.

Tissue Handling

All specimens were obtained during routine surgery. The tissues were snap frozen in liquid nitrogen shortly after surgical removal and stored at –80°C. A part of each frozen tumor sample was also embedded in paraffin. Sections of each paraffin block were stained with hematoxylin and eosin to confirm the exact tissue analyzed and to determine the proportion of tumor cells in the sample (it had to be more than 80% in tumor samples). Frozen sections adjacent to those used for histopathologic analysis were used for RNA, immunohistochemical, and FACS analysis. For [³H]-Thy labeling, fresh resected samples were collected into sterile vessels containing RPMI 1640 medium with 10% heat-inactivated fetal calf serum and brought to the laboratory immediately. All persons gave their informed consent prior to their inclusion, and the local ethics committees approved the study.

Immunohistochemistry

IMMUNOHISTOCHEMICAL DETECTION OF P21 PROTEIN. Immunohistochemical analysis was done on frozen sections. The method described by Pavelić et al.

Table 1. *FHIT* gene status, p21 expression, and [³H]-thymidine labeling in patients with synchronous dysplasia, CIS, and HNSCC.

| Patient No. | Normal Adjacent to Lesion | | | Dysplasia | | | CIS | | | Cancer | | |
|-------------|---------------------------|-----|----------------------|---------------|-----|----------------------|---------------|-----|----------------------|---------------|-----|----------------------|
| | FHIT | p21 | ³ H-[Thy] | FHIT | p21 | ³ H-[Thy] | FHIT | p21 | ³ H-[Thy] | FHIT | p21 | ³ H-[Thy] |
| 1 | N | 3 | 1.7 | N | 1 | 2.3 | N | 3 | 1.9 | At + Em (8) | 1 | 9.7 |
| 2 | N | 3 | 2.7 | At + Em (4-8) | 0 | 4.3 | At + Em (4-8) | 0 | 5.4 | At + Em (4-8) | 0 | 5.5 |
| 3 | At + Em (4-8) | 0 | 2.0 | At + Em (4-8) | 0 | 3.8 | At + Em (4-8) | 0 | 2.1 | At + Em (4-8) | 1 | 4.5 |
| 4 | At + Em (8) | 1 | 5.9 | At + Em (8) | 1 | 4.2 | At + Em (8) | 0 | 3.3 | At + Em (8) | 0 | 3.8 |
| 5 | N | 2 | 0.8 | N | 2 | 1.5 | N | 1 | 4.0 | N | 0 | 4.9 |
| 6 | N | 2 | 1.9 | N | 2 | ND | N | ND | 4.0 | N | 0 | 3.9 |
| 7 | At + Em (5-7) | 1 | 4.4 | At + Em (5-7) | 0 | 3.0 | At + Em (5-7) | 1 | 7.9 | At + Em (5-7) | 0 | 10.1 |
| 8 | N | ND | ND | N | ND | ND | At + Em (4-8) | ND | 12.7 | At + Em (4-8) | 0 | 14.1 |
| 9 | N | 3 | 2.9 | N | 2 | ND | N | 1 | 3.4 | At + Em (4-8) | 1 | ND |
| 10 | N | 3 | ND | N | 2 | 7.6 | At + Em (8) | 0 | 7.0 | At + Em (8) | 0 | 10.8 |
| 11 | N | 2 | ND | At + Em (8) | 0 | ND | At + Em (8) | 1 | ND | At + Em (8) | 1 | ND |
| 12 | N | 3 | 1.0 | N | 3 | 1.9 | N | ND | 4.1 | N | 2 | 7.1 |

N, normal; ND, not determined; At, aberrant transcript; Em, exon missing (number of exon); [³H]-Thy, [³H]-thymidine labeling × 10³; CIS, carcinoma in situ; HNSCC, squamous cell carcinoma of the head and neck.

Table 2. *FHIT* gene status, smoking status, tumor stage, p21 expression, [³H]-thymidine labeling, and apoptosis in lung cancer.

| Case No. | Lung Cancer Type | S/A Status | Stage | FHIT Status | p21 | [³ H]-Thy | Apoptosis (%) |
|----------|------------------|------------|--|----------------|-----|-----------------------|---------------|
| 1 | Adenocarcinoma | S | T ₂ N ₀ M ₀ | At + Em (8) | 0 | 4.5 | 47 |
| 2 | Adenocarcinoma | S | — | At + Em (8) | 0 | 3.9 | 22 |
| 3 | Adenocarcinoma | S | T ₂ N ₂ M ₀ | NAt + Em (4-8) | 0 | 17.1 | 11 |
| 4 | Adenocarcinoma | S | T ₃ N ₂ M ₂ | NAt + Em (5-7) | 1 | 10.0 | 15 |
| 5 | Adenocarcinoma | S | T ₂ N ₀ M ₀ | N | 3 | 2.0 | 59 |
| 6 | Squamous cell | S | T ₄ N ₃ M ₁ | N | 3 | 1.7 | 67 |
| 7 | Squamous cell | NK | T ₃ N ₂ M ₁ | NAt + Em (8) | 1 | 5.7 | 22 |
| 8 | Squamous cell | S | T ₃ N ₂ M ₁ | NAt + Em (5-7) | 2 | 7.3 | 22 |
| 9 | Squamous cell | S | T ₄ N ₃ M ₁ | NAt + Em (8) | 0 | 9.4 | 18 |
| 10 | Squamous cell | S | T ₃ N ₂ M ₀ | NAt + Em (8) | 0 | 9.7 | 5 |
| 11 | Squamous cell | S | T ₂ N ₂ M ₀ | NAt + Em (8) | 1 | 4.9 | 14 |
| 12 | Squamous cell | S | T ₂ N ₀ M ₀ | At + Em (4-7) | 0 | 7.3 | 29 |
| 13 | Squamous cell | S | T ₂ N ₀ M ₀ | At + Em (4-7) | 1 | 9.9 | 12 |
| 14 | Squamous cell | S | T ₃ N ₃ M ₁ | At + Em (4-7) | 1 | 4.6 | 17 |
| 15 | Squamous cell | S | T ₂ N ₀ M ₀ | NAt + Em (8) | 0 | 9.0 | 21 |
| 16 | Squamous cell | S | T ₃ N ₂ M ₁ | NAt + Em (8) | 0 | 7.6 | 20 |
| 17 | Large cell | S | T ₃ N ₂ M ₀ | At + Em (5-7) | 1 | 5.5 | 15 |
| 18 | Large cell | NK | — | NAt + Em (4-8) | 1 | 7.3 | ND |
| 19 | Large cell | S | T ₂ N ₀ M ₀ | NAt + Em (4-8) | 0 | 7.8 | ND |
| 20 | Large cell | S | T ₃ N ₃ M ₁ | NAt + Em (4-8) | 0 | 3.9 | 27 |

N, normal; ND, not determined; At, aberrant transcript; Em, exon missing (number of exon); [³H]-Thy, [³H]-thymidine labeling (×10³); S; smoking history; NK, not known.

Table 3. LOH of *FHIT* allele in lung tumors and HNSCC.

| Cancer Type | No. of Cases | LOH at D3S1300 | LOH at D3S4103 |
|----------------------|--------------|----------------|----------------|
| Lung adenocarcinoma | 5 | 5/5 | 4/5 |
| Lung squamous cell | 10 | 10/10 | 10/10 |
| Lung adenosquamous | 6 | 2/6 | 3/6 |
| Lung large cell | 7 | 4/7 | 5/7 |
| Total | 28 | 21/28 | 22/28 |
| HNSCC—tongue | 10 | 9/10 | 9/10 |
| HNSCC—tonsil | 7 | 7/7 | 6/7 |
| HNSCC—alveolar ridge | 4 | 2/4 | 2/4 |
| HNSCC—retromolar | 2 | 2/2 | 1/2 |
| Total | 23 | 20/23 | 18/23 |

(20) was used. Briefly, the tissue sections were fixed and the endogenous peroxidase activity was quenched by 15-min incubation in methanol containing 3% hydrogen peroxide (Sigma, Taufkirchen, Germany). Nonspecific binding was blocked by applying normal rabbit serum in a humidity chamber at a dilution of 1:10 for 30 min. Primary mouse mAb to p21^{Waf1} (Oncogene Science, Cambridge, MA) at a concentration of 5 µg/ml were applied overnight at 4°C. The secondary antibody (rabbit to mouse immunoglobulins; DAKO, Glostrup, Denmark) was applied for 1 hr at room temperature. Peroxidase-antiperoxidase (PAP, DAKO, Glostrup, Denmark) conjugate diluted 1:100 in phosphate-buffered saline (PBS) was applied for 45 min at room temperature. The slides were stained with diaminobenzidine tetrahydrochloride (DAB, Sigma) and then counterstained with hematoxylin. Finally, the slides were mounted in Canada balsam. Specificity controls comprised preabsorption of monoclonal antibodies with their appropriate antigen/peptides as recommended by the manufacturer. Antibodies were titrated to the lowest dilution having acceptable background staining.

The localization and level of specific immunostaining for each slide was evaluated in the whole tumor area. The relative level of specific immunostaining and its localization were judged. The relative intensity of cell immunostaining was evaluated, semiquantitatively, so that no staining was denoted (0), weak staining was denoted (1), moderate (2), and strong (3).

IMMUNOHISTOCHEMICAL DETECTION OF *FHIT* PROTEIN. Immunohistochemical analysis was done retrospectively. Resected tumors were fixed in a 10% formaldehyde solution and embedded in paraffin. Four-micrometer sections were cut and mounted on slides.

Staining was performed using the avidin-biotin method. Anti-*FHIT* polyclonal antibody (F-130, 1:180 dilution; IBL, Gumma, Japan) was used for *FHIT* detection. Sections were incubated 12 hr at 4°C with antibody in PBS containing 5% goat serum and were counterstained with hematoxylin. To evaluate the specificity of the antibody, the absorption test was done using *FHIT* antigen peptide according to manufacturer's instruction. For the negative control, the primary antibody was replaced with normal rabbit serum. As positive control we used tumor tissue with the wild-type of *FHIT* gene (HPSCC, case # 7, Table 1).

The intensity of staining was evaluated in four areas of the slide section for correlation and confirmation of the tissue analysis. Criteria for the analysis were as follows: no staining or very weak staining was classified as negative staining, heterogenous staining and weak staining was classified as reduced staining, and strong staining was classified as positive staining (21).

DNA LOH Analysis

All specimens were examined by routine hematoxylin-eosin staining to determine the proportion of tumor cells in the sample (it had to be more than 80%). Control normal DNA was extracted from corresponding histologically normal tissue of the patients. DNA extraction was performed using proteinase K digestion and phenol chloroform extraction. To analyze LOH at the *FHIT* gene, we used D3S1300 dinucleotide repeat and D3S4103 trinucleotide repeat. Genomic DNA (200 ng) was used as a template in a reaction volume of 25 µl containing 5 pmol of each specific primer (21,22), 50 µM of each dNTP, and 1 U *Taq* DNA polymerase (BioSystems, Warrington, United Kingdom). Polymerase chain reactions (PCR) were carried out in a BioSystems Ther-

mocycler 2400 for 30 cycles. Annealing temperatures for each set of primers were optimized in pilot studies before processing experimental samples.

For microsatellite analysis 5 μ l of PCR product were mixed with 3 μ l of loading buffer and loaded onto 1-mm thick, 35 \times 30 cm, 10% nondenaturing polyacrylamide gel. Electrophoresis was performed in 1 \times Tris/borate/EDTA buffer for 18 hr at 400 V, at room temperature. The gels were silver stained.

LOH was defined by visible change in allele: allele ratio in tumors compared with matching normal tissue. Allelic deletion of *FHIT* was judged by a positive LOH at any of the two sites.

RNA Extraction and Reverse Transcription PCR

For total RNA extraction, tumor tissue samples were homogenized in 1 ml of a solution containing 4 mM guanidinium thiocyanate, 25 mM sodium citrate, pH 7.0, 5 g/l sarcosyl, and 0.1 M/l 2-mercaptoethanol. The subsequent procedure was the same as described previously (23).

For reverse transcription (42°C for 1 hr), 5 μ g denatured RNA (10 min, 70°C), 2 μ l 10 \times reverse transcriptase buffer (500 mM Tris HCl, pH 8.3, 300 mM KCl, 80 mM MgCl₂, 100 mM dithiothreitol; New England BioLabs Inc.), 200 μ M each dNTPs, 25 U Moloney Murine Leukemia Virus reverse transcriptase (New England BioLabs Inc., Frankfurt am Main, Germany), and 0.4 mM oligo (dT)18 were used in a total volume of 20 μ l. The cDNA was heat denatured (95°C, 5 min) before PCR and then amplified in separate tubes with primers for the human β -actin gene and/or with primers for *FHIT* gene.

FHIT Expression Analysis

Half of microliter of cDNA was used for PCR amplifications with primers 5U2 and 3D2 from *FHIT* exons 1 and 10, respectively (3). Amplification was carried out in 25 μ l volume. The PCR mixture consisted of 0.5 μ l of cDNA, 2.5 μ l of 10 \times PCR buffer II (Bio Systems), 1.5 mM of MgCl₂, 50 μ M of each dNTP, 5 pmol of each specific primer, and 1 U of *Taq* DNA polymerase (Bio Systems, Warrington, United Kingdom). The PCR consisted of an initial denaturation step at 95°C for 5 min, followed by 45 cycles of 30 sec at 96°C, 30 sec at 56°C, and 45 sec at 72°C. Final extension lasted 10 min. The PCR products were resolved by agarose gel electrophoresis (1.5% agarose stained with 0.5 μ g/ml ethidium bromide).

Proliferation Assay

Tumor cell kinetics were evaluated by the thymidine-labeling index (24). Tumor fragments were incubated immediately after surgery for 1 hr at 37°C with shaking in 1640 RPMI medium with 15% of fetal calf serum and 5% of normal human serum, 1% L-glutamine, 100 mg/ml of streptomycin, 100 U/

ml of penicillin, and 6 mCi/ml of [³H]-thy (5 Ci/mmol; Amersham Pharmacia, Zagreb, Croatia). Tumor cell kinetic was expressed as the count per minute (cpm) of labeled cells among the total number of tumor cells. A minimum of 2000 cells was scored for each sample.

Analysis of Apoptosis

DNA LADDER. DNA fragments were isolated according to the method described by Herrmann et al. (25). Tumor tissue was disaggregated, pelleted by centrifugation, and washed two times in PBS. Afterward, the cells were resuspended for 10 sec in 100 μ l of lysis buffer (1% NP-40 in 20 nM of EDTA, 50 mM of Tris-HCl, pH 7.5) and centrifuged for 5 min at 3000 g. The supernatant was transferred to a new Eppendorf tube while the pellet was incubated once more with 100 μ l of lysis buffer and centrifuged as before. The supernatants were pooled together and incubated for 2 hr in 1% SDS and RNase (5 μ g/ μ l) at 56°C after which the proteinase K was added in final concentration 2.5 mg/ml overnight. DNA fragments were pelleted by addition of 1/2 volume of 10 M ammonium acetate and 2.5 volume of prechilled absolute ethanol. After centrifugation (30 min, 12,000 g), the pellet was washed with 70% ethanol, centrifuged for 10 min at 12,000 g, dried, dissolved in 20 μ l of TE buffer (10 mM of Tris HCl, pH 7.4; 1 mM of EDTA, pH 8.0). The DNA was visualized on 1.5% agarose gel.

FACSCAN ANALYSIS. FACScan analysis of apoptosis was performed according to the procedure of Sard et al. (16). Two million cells per sample were fixed with 2% paraformaldehyde in PBS, washed twice with TBS (50 mM Tris HCl in saline solution), and permeabilized for 1 min with ice cold acetone. Staining was performed by incubating cells for 1 hr at 37°C in 25 μ l of TUNEL reaction mixture—in situ Cell Death Detection Kit (Boehringer, Mannheim, Germany). Samples were analyzed by FACScan (Becton Dickinson, Erembodegem-Aalst, Belgium).

Statistical Analysis

Descriptive statistics are presented as mean \pm standard deviation. For ordinary data, descriptive statistics are presented with median and percentiles or as percentages. The correlation between p21 score and *FHIT* gene status was calculated from a contingency table. The table was analyzed with Fisher's exact test. Box-Whisker plots were generated in the basic module of the program Statistica. The correlation between apoptosis and *FHIT* gene status was analyzed with the Wilcoxon rank-sum test. Kaplan-Meier curves were generated for the analysis of time of death (LIFETEST procedure in SAS/Stat). Differences in survival time between groups were compared by the log-rank and Wilcoxon tests (also LIFETEST procedure in SAS/Stat).

Results

Status of *FHIT* gene, expression of p21^{waf1}, cell proliferation, and apoptosis were analyzed in head and neck and lung tumor tissues by molecular genetic methods, immunohistochemistry, DNA, and reverse transcription PCR (RT-PCR) analysis, [³H]-thy labeling method, and FACScan analysis in snap-frozen tissues and paraffin-embedded tissue sections.

Expression of the *FHIT* and p21^{waf1} genes in HNSCCs and in lung carcinomas was analyzed by immunohistochemistry on frozen sections or archival formalin-fixed, paraffin-embedded tissue sections, respectively. Figure 1 shows *FHIT* protein and p21^{waf1} immunostaining of surgically resected HNSCC and lung cancers. The observed staining pattern was essentially similar in all specimens and was represented by the nuclear (p21^{waf1}) or cytoplasmic (*FHIT* protein) staining of tumor cells with the negative surrounding tissue for the both proteins. Of the 120 HNSCC studied, 64 (53%) stained positively for *FHIT* protein and 20 (17%) stained positively for p21^{waf1}. Of the 82 lung cancers studied, 25 (30%) stained positively for *FHIT* protein and 21 (26%) stained positively for p21^{waf1}. All control sections, which were incubated with nonspecific IgG instead of the primary monoclonal antibody, were also uniformly negative.

Survival Analysis

In an exploratory, analysis we examined the relationship between outcome of patients suffering from HNSCC monitored in 100-month period and *FHIT* immunoreactivity results. Survival analysis was performed on 82 patients suffering from lung cancer. The survival curves according to *FHIT* protein expression are shown in Figure 2A. The median

survival time of patients without *FHIT* expression was 22.46 months and that of the patients with *FHIT* protein expression 36.04 months. *FHIT*-negative cases tended to correlate with a worse prognosis; however, this probability did not reach statistical significance. Finally, we analyzed the survival rate of *FHIT*-positive and *FHIT*-negative cases of patients classified as having stage III head and neck cancer. Survival analysis was performed on 66 patients monitored over a 130-month period. The median survival time of patients without *FHIT* protein expression was 30.86 months and that of the patients with *FHIT* protein expression was 64.04 months. Statistical analysis showed that patients with tumors that were negative for *FHIT* protein survived significantly longer ($p < 0.05$) (Fig. 2B).

FHIT Gene Status Analysis

FHIT gene status was examined by RT-PCR analysis for the presence of aberrant *FHIT* transcripts. Twenty-three HNSCC and 20 lung cancers were examined (Tables 3 and 4). According to the results, tumor samples were divided into two categories: *FHIT* normal and *FHIT* aberrant. The results of *FHIT* gene status by RT-PCR are shown in Figure 3. The size of normal PCR product (normal *FHIT* gene status) is 814 bp, and the sizes of aberrant products are from 350–690 bp. RT-PCR products were directly sequenced after isolation of bands from low melting agarose and purification on columns (QIAGEN, Hilden, Germany). Sequencing of PCR products was performed as described previously (3).

Analysis of Synchronous Head and Neck Lesions

Table 1 summarizes the results of *FHIT* gene status, p21^{waf1} expression, and [³H]-thy labeling in synchronous combinations of normal, precancerous,




Fig. 1. Immunohistochemical analysis of p21^{waf1} (A and B) and *FHIT* (C and D) proteins in HNSCC.




Fig. 2. Kaplan-Meier survival curves after curative resection of FHIT protein positive and FHIT negative carcinomas. (A) Lung cancer. (B) HNSCC.




Fig. 3. Expression of the *FHIT* gene in HNSCC by RT-PCR analysis. M, DNA marker; Lane 1, normal transcript 814 bp; Lanes 2-4, aberrant transcripts.

and cancerous head and neck tissues. The majority of the malignant lesions (7 of 12) displayed aberration of *FHIT* gene, together with low or negative expression of *p21^{waf1}* and increased intensity of cell proliferation (increased [³H]-thy incorporation). *FHIT* gene aberration consisted of missing exons (exon 8, exons 4-8, or exons 5-7) and aberrant (or both aberrant and normal) transcript. In three cases of normal, adjacent-to-lesion tissue contained similar changes in *FHIT* gene, *p21^{waf1}* expression (cases 3, 4, and 7) and cell proliferation (cases 4 and 7). Five out of 12 precancerous synchronized lesions contained similar changes in *FHIT* gene, *p21^{waf1}* expression, and [³H]-thy incorporation. Exons 8, 4-8 or 5-7 were missing, and aberrant transcripts of *FHIT* gene were observed in cases 2, 3, 4, 7, and 8 together with low or negative expression of *p21^{waf1}* expression, and high intensity of [³H]-thy labeling.

The observed changes increased with progression of these lesions from normal tissue (3 of 12) and dysplasia (5 of 12) to carcinoma in situ (7 of 12) and cancer (9 of 12).

Analysis of Apoptosis

The results obtained after DNA isolation from disaggregated tumor tissues and electrophoresis on agarose gel are shown in Figure 4. DNAs isolated from two tumor tissues (lanes 3 and 7) are fragmented in small apoptotic fragments. The results obtained by FACScan analysis are shown in Table 4.

Analysis of HNSCC

Table 4 shows tumor characteristics, patient history, *FHIT* transcripts, aberrant products and missing




Fig. 4. Agarose gel electrophoresis of small (apoptotic) DNA fragments isolated from lung cancer in 1.5% agarose. M, DNA molecular weight marker; Lanes 1-8 DNAs isolated from lung cancers; Lanes 3 and 7, apoptosis.

Table 4. *FHIT* gene status, smoking and alcohol status, tumor stage, p21 expression, [³H]-thymidine labeling, and apoptosis in HNSCC.

| Case No. | Tumor Site | S/A Status | Stage | <i>FHIT</i> Status | p21 | [³ H]-Thy | Apoptosis(%) |
|----------|----------------|------------|---|--------------------|-----|-----------------------|--------------|
| 1 | Tongue | SA | T ₂ N _{2b} M _X | At + Em (8) | 1 | 8.6 | 7 |
| 2 | Tongue | S | T ₂ N ₀ M _X | At + Em (8) | 2 | 12.5 | 12 |
| 3 | Tongue | S | T ₃ N _{2b} M _X | At + Em (4–8) | 1 | 7.8 | 25 |
| 4 | Tongue | SA | T ₂ N ₀ M _X | N | 3 | 1.5 | 63 |
| 5 | Tongue | SA | T ₁ N ₀ M _X | At + Em (4–8) | 1 | 19.0 | 19 |
| 6 | Tongue | SA | T ₁ N ₁ M _X | At + Em (5–7) | 1 | 7.5 | 30 |
| 7 | Tongue | SA | T ₂ N ₀ M _X | N | 3 | 2.0 | 58 |
| 8 | Alveolar ridge | S | T ₂ N ₀ M _X | At + Em (8) | 0 | 12.7 | 14 |
| 9 | Alveolar ridge | S | T ₂ N ₀ M _X | At + Em (4) | 1 | ND | 31 |
| 10 | Alveolar ridge | SA | T ₁ N ₀ M _X | At + Em (5–8) | 2 | 19.5 | 16 |
| 11 | Alveolar ridge | A | T ₁ N ₁ M _X | N | 3 | 2.5 | 65 |
| 12 | Alveolar ridge | S | T ₂ N ₂ M _X | N | 1 | 3.5 | 49 |
| 13 | Alveolar ridge | SA | T ₂ N ₀ M _X | At + Em (4–8) | 1 | 7.7 | 17 |
| 14 | Tonsil | — | T ₃ N ₁ M _X | At + Em (8) | 1 | 18.0 | 23 |
| 15 | Tonsil | A | T ₄ N _{2b} M _X | At + Em (8) | 1 | 9.9 | 29 |
| 16 | Tonsil | SA | T ₂ N ₁ M _X | At + Em (4–8) | 1 | ND | 11 |
| 17 | Tonsil | SA | T ₄ N _{2b} M _X | N | 3 | 2.5 | 70 |
| 18 | Tonsil | — | T ₂ N ₀ M _X | N | 3 | 1.7 | 59 |
| 19 | Retromolar | SA | T ₁ N ₀ M _X | N | 2 | 4.5 | 76 |
| 20 | Retromolar | SA | T ₂ N _{2b} M _X | At + Em (8) | 1 | 2.1 | 18 |
| 21 | Retromolar | S | T ₁ N ₀ M _X | At + Em (5–7) | 1 | 10.9 | 27 |
| 22 | Retromolar | SA | T ₂ N _{2b} M _X | At + Em (4–8) | 1 | ND | 14 |
| 23 | Retromolar | S | T ₂ N _{2b} M _X | At + Em (8) | 1 | 9.1 | 23 |

N, normal; ND, not determined; At, aberrant transcript; Em, exon missing (number of exon); [³H]-Thy, [³H]-thymidine labeling ($\times 10^3$); S, smoking; A, alcohol.

exons, and expression of p21, [³H]-thy incorporation and intensity of apoptosis in HNSCC. Twenty-three HNSCC were analyzed by RT-PCR for the presence of aberrant *FHIT* transcripts. RNA was isolated, reverse transcribed, and amplified by PCR using primers derived from exons 1 and 10 of the *FHIT* gene. Aberrant transcripts were observed in 16 of 23 (70%) tumor samples. Amplified products from most tumors with aberrant transcripts showed both normal and abnormal sized products.

p21^{Waf1} was over-expressed in five tumors, and moderately expressed in three tumors, mostly in those with normal *FHIT* gene status. Tumors with aberrant *FHIT* gene showed very low expression of p21^{Waf1}. These tumors incorporated a higher amount of [³H]-thy than tumors with normal *FHIT* gene. Percentage of apoptosis was also in concordance to *FHIT* gene status. Tumors with aberrant *FHIT* showed much lower intensity of apoptosis in comparison to tumors with normal *FHIT* gene.

Analysis of Lung Cancer

Table 4 shows similar results in lung tumors. Eighteen out of 20 tumors showed aberrant *FHIT* gene status. Lung carcinomas with aberrant *FHIT* gene status had generally low expression of p21^{Waf1}, high proliferation activity, and low rate of apoptosis.

FHIT Status and p21^{Waf1} Expression or Apoptosis

These results were confirmed in independent experiment with HNSCC. Tumor samples were divided in two categories: *FHIT* normal (15 tissues) and *FHIT* aberrant (13 cases). In 7 cases tumor was located in tongue, 13 were located in alveolar ridge, 3 in tonsil, and 5 retromolar. Tumors were in different stages. Figures 5 and 6 show clear differences between *FHIT*-aberrant and *FHIT*-normal tumors. Figure 5 represents frequencies of normal and aberrant *FHIT* for different expression of p21. Each point on the graph represents one observation. We can see a strong correlation ($p <$

gion. Some tumors exhibited homozygous deletion within the *FHIT* gene; 55% showed the presence of multiple cell populations with losses of different portions of *FHIT* alleles by FISH of *FHIT* genomic clones to interphase nuclei.

Our results and others findings show those *FHIT* gene deletions frequently involve exons 5–9, including LOH within this chromosomal region (3). It is conceivable that these deletions affect other expressed sequences. Lux et al. (27) report on identification of five novel expressed sequence tags within 3p14.2 that map proximal to exon 9 of the candidate to tumor suppressor gene *FHIT*. These sequence tags may be valuable for elucidation of the supposed tumor suppressor gene content in 3p14.2.

Our results clearly indicate a correlation between aberrant *FHIT* gene, increased cell proliferation (low p21^{waf1} expression), and a low rate of apoptosis. Ji et al. (17) suggest that the *FHIT* gene, when delivered at high efficiency into HI2199 lung cancer cells by a recombinant adenoviral vector, functions as a tumor suppressor gene both in vitro and in vivo. Overexpression of the *FHIT* gene induced cell apoptosis and altered cell-cycle processes. The apoptotic cell population markedly increased, and cells accumulated in S-phase after *FHIT* transduction. Sard et al. (16) transferred *FHIT* gene into lung cancer cell line H460 lacking *FHIT* protein expression. Gene transfer resulted in reversion of tumorigenicity. A significant inhibition of cell growth was observed in transfected cells, and again a high rate of apoptosis induced DNA strand breaks in stable clones. FAC-Scan analysis showed an apoptotic rate of 44–47% compared with a 15% level in the control H460 cells. An increased level of p21 protein paralleled by an up-regulation of p21^{waf1} transcripts also was found in *FHIT*-expressing clones compared with the H460 cell line. Our results proved clinical relevance of transfection experiments. Observed growth inhibitory effect of *FHIT* re-expressing cells could be related to apoptosis and cell-cycle arrest and link the tumor-suppressor activity of *FHIT* protein to its proapoptotic function.

Our clinical data as well as in vitro data obtained by Sard et al. (16) strongly suggest that alteration of *FHIT* gene is associated with decreased apoptosis, p21^{waf1} expression, and increased cell proliferation. Re-expression of *FHIT* gene in H460 cells revealed a significant G₀/G₁ arrest and a presence of sub-G₁ peak. Cell-cycle analysis showed 53% of cells in G₀/G₁, 46% in S, and 1% in G₂+M phases. A significant increase in p21^{waf1} protein expression was noticed in our study as well as in *FHIT*-protein expressing clones compared with that of the control cells bearing mutant gene (16). No difference in p53 amounts was observed in the same cells suggesting a p53-independent effect. p21^{waf1} protein is a universal cell-cycle inhibitor that specifically binds cyclin–CDK complex and proliferating cell nuclear antigen, acting as a potent growth inhibitor and effector of cell-

cycle checkpoints (28,29,30). Increase in p21^{waf1} protein is directly associated with *FHIT* transcripts (16). Observed effect on G₀/G₁ cycle arrest in *FHIT*-re-expressing clones could be mediated by p21^{waf1} induction.

A role of *FHIT* protein as a proapoptotic factor is in agreement with the structural and biochemical studies indicating that *FHIT*–Ap3A complex is the active *FHIT* form involved in cellular signaling and with the recent studies linking the induction of apoptosis in human tumors to a decrease in Ap3A level (31,32).

Our results obtained on synchronous lesions showed clearly that abnormal transcripts of the *FHIT* gene sometimes could be found in non-neoplastic or premalignant tissues, although observed changes increased with progression of these lesions from normal tissue and dysplasia to carcinoma in situ and cancer. Tanimoto et al. (33) examined abnormalities of *FHIT* gene in tissue samples of HNSCC along with several leukoplakias and an erythroplakia. Aberrant transcripts could be found in two of seven premalignant lesions; interestingly, in the case of one patient with a premalignant lesion showing an abnormal *FHIT* transcript, subsequent oral squamous cell carcinoma developed during a 3-year follow-up period. On the other hand, in the two patients from whom both leukoplakia and squamous cell carcinoma samples were taken simultaneously, abnormal *FHIT* transcripts were found only in squamous cell carcinoma (33).

Our results with synchronous lesions showed that *FHIT* could be aberrant in normal, adjacent-to-tumor tissue of head and neck. Occurrence of abnormal transcripts of the *FHIT* gene has been reported in various types of cancer (6). Tokuchi very recently found that the frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung. The difference between lung cancer and paired normal lung was significant, whereas that between lung cancer and normal control lung was not. Authors concluded that the presence of abnormal *FHIT* transcripts, in terms of their frequency and variety, is not cancer-specific in lung carcinogenesis, and the abnormality may be mainly due to abnormal splicing and processing of the transcripts (6).

We found LOH in patient with HNSCC and lung cancers. Allele loss involving chromosome arm 3p is one of the most frequent and earliest known genetic events in lung cancer pathogenesis and may affect several potential tumor gene regions. In a recently published study Wistuba et al. (34) showed that 91% of small cell lung carcinomas and 95% squamous cell carcinomas demonstrated larger 3p segments of allele loss, whereas 70% of adenocarcinomas and preneoplastic/preinvasive lesions had smaller areas of 3p allele loss regions with increasing severity of histopathologic preneoplastic/preinvasive changes. Allele loss on 3p is nearly universal in lung

cancer pathogenesis and involves multiple, discrete, 3p LOH sites that often show a "discontinuous LOH" pattern in individual tumors; it occurs in preneoplastic/preinvasive lesions in smokers with and without lung cancer.

Wistube et al. (34) also found that multiple lesions often lose the same parental allele. LOH frequently involves breakpoints in at least three very small, defined genomic regions. Allele loss and break points first occur in the 600-kb 3p21.3 region.

Our results indicate a high incidence of smoking and alcohol consumption in HNSCC and high incidence of smoking history in lung cancer associated with *FHIT* aberration, a high rate of proliferation, and a low rate of apoptosis. Some other data support such observations. Cigarette smoking could induce molecular alterations of *FHIT* and p53 gene. Sozzi et al. (14) undertook a molecular study of *FHIT* and *FRA3B* microsatellite alterations in lung tumors from heavy smokers and in tumors developed in never-smokers to seek genetic damage attributable to tobacco smoking. Their findings suggest that *FHIT* is a candidate molecular target of carcinogens contained in tobacco smoke. Tobacco smoke contains a mixture of highly mutagenic compounds such as polycyclic aromatic hydrocarbons: in particular benzo(α)pyrene diol-epoxide [B(α)P], which is a major constituent of tobacco smoke. In vitro evidence for B(α)P-induced formation of DNA adducts of the major mutational hot spots of the p53 gene in human lung cancer has recently been provided (35).

Taken together, our results show a clear correlation between aberrant *FHIT* gene and a low rate of apoptosis and high rate of tumor cell proliferation. Aberrant *FHIT* gene could be a prognostic marker in lung cancer, although there is a tendency toward longer survival in HNSCC patients. It can be speculated that the *FHIT* gene is involved in progression of both lung cancers and HNSCC.

References

- Sozzi G, Veronese ML, Negrini M, et al. (1996) The *FHIT* gene at 3p14.2 is abnormal in lung cancer. *Cell* **85**: 17–26.
- Kastury K, Baffa R, Druck T, et al. (1996) Potential gastrointestinal tumor suppressor locus at the 3p14.2 *FRA3B* site identified by homozygous deletions in tumor cell lines. *Cancer Res.* **56**: 978–983.
- Ohta M, Inoue H, Cotticelli MG, et al. (1996) The human *FHIT* gene, spanning the chromosome 3p14.2 fragile site acid renal carcinoma-associated T(3-8) breakpoint, is abnormal in digestive tract cancers. *Cell* **84**: 587–597.
- Virgilio L, Shuster M, Gollin SM, et al. (1996) *FHIT* gene alterations in head and neck squamous cell carcinomas. *Proc. Natl. Acad. Sci. U.S.A.* **93**: 9770–9775.
- Lubinski J, Hadaczek P, Podolski J, et al. (1994) Common regions of deletion in chromosome regions 3p12 and 3p14.2 in primary clear cell renal carcinomas. *Cancer Res.* **54**: 3710–3713.
- Tokuchi Y, Kobayashi Y, Hayashi S, et al. (1999) Abnormal *FHIT* transcripts found in both lung cancer and normal lung tissue. *Genes Chromosomes Cancer* **24**: 105–111.
- Barnes LD, Garrison PN, Siprashvili Z, et al. (1996) *FHIT*, a putative tumor suppressor in humans, is a dinucleoside 5',5''-P¹,P³-triphosphate hydrolase. *Biochemistry* **35**: 11529–11535.
- Wang N, Perkins KL. (1984) Involvement of band 3p14 in t(3;8) hereditary renal carcinoma. *Cancer Genet. Cytogenet.* **11**: 479–481.
- Croce CM, Sozzi G, Huebner K. (1999) Role of *FHIT* in human cancer. *J. Clin. Oncol.* **17**: 1618–1624.
- Ahsee KW, Cooke TG, Pickford IR, Soutar D, Balmain A. (1994) An allelotype of squamous carcinoma of the head and neck using microsatellite markers. *Cancer Res.* **54**: 1617–1621.
- Ishwad CS, Ferrell RI, Rossie KM, et al. (1996) Loss of heterozygosity of the short arm of chromosomes 3 and 9 in oral cancer. *Int. J. Cancer* **69**: 1–4.
- Mao L, Lee JS, Fan YH, et al. (1996) Frequent microsatellite alterations of chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. *Nat Med* **2**: 682–685.
- Wu CL, Sloan P, Read AP, Harris R, Thakker N. (1994) Deletion mapping on the short arm of chromosome 3 in squamous cell carcinoma of the oral cavity. *Cancer Res.* **54**: 6484–6488.
- Sozzi G, Sard L, De Gregorio L, et al. (1997) Association between cigarette smoking and *FHIT* gene alterations in lung cancer. *Cancer Res.* **57**: 2121–2123.
- Siprashvili Z, Sozzi G, Barnes LD, et al. (1997) Replacement of *FHIT* in cancer cells suppresses tumorigenicity. *Proc. Natl. Acad. Sci. U.S.A.* **94**: 13771–13776.
- Sard L, Accornero P, Torielli S, et al. (1996) The tumor-suppressor gene *FHIT* is involved in the regulation of apoptosis and in cell cycle control. *Proc. Natl. Acad. Sci. U.S.A.* **96**: 8489–8492.
- Ji L, Fang BL, Yen N, Fong K, Minna JD, Roth JA. (1999) Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (*FHIT*) gene overexpression. *Cancer Res.* **59**: 3333–3339.
- Fong LYY, Fidanza V, Zanesi N, et al. (2000) Muir-Torre-like syndrome in *FHIT*-deficient mice. *Proc. Natl. Acad. Sci. U.S.A.* **97**: 4742–4747.
- Spaventi R, Pečur L, Pavelić K, Pavelić ZP, Spaventi Š, Stambrook PJ. (1994) Human tumor bank in Croatia: a possible model for a small bank as a part of the future European tumor bank network. *Eur. J. Cancer* **30A**: 419–419.
- Pavelić K, Pavelić ZP, Denton D, Reising J, Khalily M, Preisler HD. (1990) Immunohistochemical detection of C-MYC oncoprotein in paraffin embedded tissue. *J. Exp. Pathol.* **5**: 143–153.
- Baffa R, Veronese ML, Santoro R, et al. (1998) Loss of *FHIT* expression in gastric carcinoma. *Cancer Res.* **58**: 4708–4714.
- Druck T, Hadaczek P, Fu TB, et al. (1997) Structure and expression of the human *FHIT* gene in normal and tumor cells. *Cancer Res.* **57**: 504–512.
- Gall-Trošelj K, Kušić B, Pečina-Šlaus N, Pavelić K, Pavelić J. (1995) Nested polymerase chain reaction for detection of hepatitis C virus RNA in blood derivatives. *Eur. J. Clin. Chem. Clin. Biochem.* **33**: 733–736.
- Pavelić K, Kapitanović S, Radošević S, et al. (2000) Increased activity of *nm23-H1* gene in squamous cell carcinoma of the head and neck is associated with advanced disease and poor prognosis. *J. Mol. Med.* **78**: 111–118.
- Herrmann M, Lorenz HM, Voll R, Grunke M, Woith W, Kalden JR. (1994) A rapid and simple method for the isolation of apoptotic DNA fragments. *Nucleic Acids Res.* **22**: 5506–5507.
- Fong KM, Biesterveld EJ, Virmani A, et al. (1997) *FHIT* and *FRA3B* 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related *FHIT* cDNA splicing aberrations. *Cancer Res.* **57**: 2256–2267.
- Lux A, Bardenhener W, Michael D, et al. (1997) Identification of novel expressed sequence tags within the *FHIT* gene locus in human chromosome region 3p14.2. *Hum. Genet.* **100**: 90–95.
- Eldeiry WS, Tokino T, Velculescu VE, et al. (1993) WAF1, a potential mediator of p53 tumor suppression. *Cell* **75**: 817–825.
- Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. (1993) The p21 CDK-interacting protein CIP1 is a potent inhibitor of G1 cyclin-dependent kinases. *Cell* **75**: 805–816.

30. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. (1993) p21 is a universal inhibitor of cyclin kinases. *Nature* **366**: 701–704.
31. Pace HC, Carrison PN, Robinson AK, et al. (1998) Genetic, biochemical, and crystallographic characterization of FHIT-substrate complexes as the active signaling form of FHIT. *Proc. Natl. Acad. Sci. U.S.A.* **95**: 5484–5489.
32. Kisselev LL, Justesen J, Wolfson AD, Frolova LY. (1998) Diadenosine oligophosphates (AP(N)A), a novel class of signaling molecules. *FEBS Lett.* **427**: 157–163.
33. Tanimoto K, Hayashi S, Tsuchiya E, et al. (2000) Abnormalities of the *FHIT* gene in human oral carcinogenesis. *Br. J. Cancer* **82**: 838–843.
34. Wistuba II, Behrens C, Virmani AK, et al. (2000) High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. *Cancer Res.* **60**: 1949–1960.
35. Denissenko MF, Pao A, Tang M, Pfeifer GP. (1996) Preferential formation of benzo[α]pyrene adducts at lung cancer mutational hotspots in p53. *Science* **274**: 430–432.